Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galera TherapeuticsGRTXD -1.02%35 EBIT per Share is $-11.63 as of Mar. 2026. GuruFocus rates GRTXD with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,173 Biotechnology companies, Galera Therapeutics ranks better than 93.44% on this metric.
Galera Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-3.36.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.63.
During the past 3 years, the average EBIT per Share Growth Rate was 68.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 53.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Galera Therapeutics's EBIT per Share or its related term are showing as below:
GRTXD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.5 Med: 38.45 Max: 68.2
Current: 68.2
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Galera Therapeutics was 68.20% per year. The lowest was -31.50% per year. And the median was 38.45% per year.
GRTXD's 3-Year EBIT Growth Rate is ranked better than 93.44% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs GRTXD: 68.20
Galera Therapeutics (OTCPK:GRTXD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Galera Therapeutics EBIT per Share Related Terms
Galera Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Galera Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galera Therapeutics (GRTXD) has a EBIT per Share of $-11.63 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Galera Therapeutics and its competitors. According to the industry distribution chart, Galera Therapeutics ranks #77 out of 1173 companies in the Biotechnology industry, placing it in the top 6.6%.
Is Galera Therapeutics' EBIT per Share too high?
Galera Therapeutics' current EBIT per Share is $-11.63. Based on the distribution chart, Galera Therapeutics ranks #77 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Galera Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Galera Therapeutics' EBIT per Share compare to CELU and BCDA?
According to the Biotechnology industry distribution chart, Galera Therapeutics ranks #77 out of 1173 companies for EBIT per Share. This places Galera Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Galera Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galera Therapeutics's current EBIT per Share is $-11.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galera Therapeutics stock overvalued right now?
Galera Therapeutics (GRTXD) has a current EBIT per Share of $-11.63. The current EBIT per Share is $-11.63. Galera Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Galera Therapeutics (GRTXD), the current EBIT per Share is $-11.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galera Therapeutics Inc is a biopharmaceutical company that historically was focused on developing a portfolio of small-molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, mainly by reducing one of the common side effects of radiotherapy, severe oral mucositis (SOM). Superoxide Dismutase Mimetics: excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galera's SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advance breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion.
35GF Score
Get the complete analysis for GRTXD
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRTXD has been successfully added to your 
